TXG
10x Genomics, Inc.NASDAQHealthcare$22.33+1.27%ClosedMarket Cap: $2.85B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.56
P/S
4.44
EV/EBITDA
-202.38
DCF Value
$-12.66
FCF Yield
4.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.1%
Operating Margin
-9.5%
Net Margin
-6.8%
ROE
-5.7%
ROA
-4.5%
ROIC
-6.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $166.0M | 68.1% | $-19.5M | $-16.3M | $-0.13 | — |
| FY 2025 | $642.8M | 69.1% | $-110.9M | $-43.5M | $-0.35 | — |
| Q3 2025 | $149.0M | 67.3% | $-32.2M | $-27.5M | $-0.22 | — |
| Q2 2025 | $172.9M | 72.3% | $30.1M | $34.5M | $0.28 | — |
| Q1 2025 | $154.9M | 68.1% | $-39.3M | $-34.4M | $-0.28 | — |
| Q4 2024 | $165.0M | 67.2% | $-49.8M | $-49.0M | $-0.40 | — |
| FY 2024 | $610.8M | 67.9% | $-194.6M | $-182.6M | $-1.52 | — |
| Q3 2024 | $151.7M | 70.2% | $-41.5M | $-35.8M | $-0.30 | — |
| Q2 2024 | $153.1M | 68.1% | $-41.7M | $-37.9M | $-0.32 | — |
| Q1 2024 | $141.0M | 65.9% | $-61.5M | $-59.9M | $-0.50 | — |
| Q4 2023 | $184.0M | 62.9% | $-55.2M | $-49.0M | $-0.41 | — |
| FY 2023 | $618.7M | 66.2% | $-265.3M | $-255.1M | $-2.18 | — |